Purpose of this Study
We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.
Who Can Participate?
Eligibility
Adults 18 and older who:
- Have lung cancer that has been removed while on Duke Cancer Study A151216
- Had their surgery between 33-77 days ago
- Are negative for the genetic markers EGRF and ALK
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will get a random assignment (fair, equal chance) to 1 of 3 groups:
One group will receive only chemotherapy for 3 months
Another group will receive chemotherapy for 3 months followed by immunotherapy for up to 1 year
A third group will receive chemotherapy and immunotherapy together for 3 months followed by immunotherapy for up to 10 months
Regardless of group assignment, all study participants will:
- Get check-ups from your doctor every 3 months for the first 2 years after treatment
- Get check-ups from your doctor every 6 months for the 3rd, 4th, and 5th years after treatment
- Get a yearly check-up from your doctor for 5 more years once you hit the 5-year mark after treatment
Locations
Duke University Hospital
Duke Raleigh Hospital
Other
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
Alliance A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO
Principal Investigator
Jeffrey
Crawford
Protocol Number
PRO00106593
NCT ID
NCT04267848
Phase
III
Enrollment Status
Open to Enrollment